Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer

Top Quote Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. End Quote
  • (1888PressRelease) June 07, 2011 - Women who received Avastin experienced a 52 percent reduction in the risk of their disease progressing (HR = 0.48, p

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information